The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Open accessAbstract
PURPOSE: The phase III POLO study demonstrated significant progression-free survival (PFS) benefit for active olaparib maintenance therapy versus placebo for patients with metastatic pancreatic adenocarcinoma and a germline BRCA mutation. Here, we report the final analysis of overall survival (OS) and other secondary end points. PATIENTS AND METHODS: Patients with a deleterious or suspected deleterious germline BRCA mutation whose disease had not progressed after ≥ 16 weeks of first-line platinum-based chemotherapy were randomly assigned 3:2 to active maintenance olaparib (300 mg twice daily) or placebo. The primary end point was PFS; secondary end points included OS, time to second disease progression or death, time to first and second subsequent cancer therapies or death, time to discontinuation of study treatment or death, and safety and tolerability. RESULTS: In total, 154 patients were randomly assigned (olaparib, n = 92; placebo, n = 62). No statistically significant OS benefit was observed (median 19.0 v 19.2 months; hazard ratio [HR], 0.83; 95% CI, 0.56 to 1.22; P = .3487). Kaplan-Meier OS curves separated at approximately 24 months, and the estimated 3-year survival after random assignment was 33.9% versus 17.8%, respectively. Median time to first subsequent cancer therapy or death (HR, 0.44; 95% CI, 0.30 to 0.66; P < .0001), time to second subsequent cancer therapy or death (HR, 0.61; 95% CI, 0.42 to 0.89; P = .0111), and time to discontinuation of study treatment or death (HR, 0.43; 95% CI, 0.29 to 0.63; P < .0001) significantly favored olaparib. The HR for second disease progression or death favored olaparib without reaching statistical significance (HR, 0.66; 95% CI, 0.43 to 1.02; P = .0613). Olaparib was well tolerated with no new safety signals. CONCLUSION: Although no statistically significant OS benefit was observed, the HR numerically favored olaparib, which also conferred clinically meaningful benefits including increased time off chemotherapy and long-term survival in a subset of patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“longer follow up data did not demonstrate a similar improvement in overall survival (OS) compared to patients who received placebo alone following platinum-based therapy88.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [88]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Siegel, R. L., Miller, K. D., & Jemal, A. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21590 · Cited by 20,444
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Self-citationInhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Moore, K., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., Sonke, G. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810858 · Cited by 2,870
Whole genomes redefine the mutational landscape of pancreatic cancer
Initiative, A. P. C. G., Waddell, N., Pajic, M., Patch, A.-M., Chang, D. K., Kassahn, K. S., Bailey, P., Johns, A. L., Miller, D., Nones, K., et al. (2015) · Nature · doi:10.1038/nature14169 · Cited by 2,642
Self-citationMaintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer
Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., Park, J.-O., Hochhauser, D., Arnold, D., Oh, D.-Y., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903387 · Cited by 2,302
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- Friedenson B, 2005, MedGenMed, 7, 60
Cited by
Sorted by citations
Pancreatic cancer: Advances and challenges
Halbrook, C. J., Lyssiotis, C. A., Pasca di Magliano, M., & Maitra, A. (2023) · Cell · doi:10.1016/j.cell.2023.02.014 · Cited by 1,321
Stoop, T. F., Javed, A. A., Oba, A., Koerkamp, B. G., Seufferlein, T. T. W., Wilmink, J. W., & Besselink, M. G. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00261-2 · Cited by 601
Therapeutic developments in pancreatic cancer
Hu, Z., & O'Reilly, E. M. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00840-w · Cited by 438
Self-citationMosele, M. F., Westphalen, C. B., Stenzinger, A., Barlési, F., Bayle, A., Bièche, I., Bonastre, J., Castro, E., Dienstmann, R., Krämer, A., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.04.005 · Cited by 468
Molecular tumour boards — current and future considerations for precision oncology
Tsimberidou, A. M., Kahle, M., Vo, H. H., Baysal, M. A., Johnson, A. M., & Meric‐Bernstam, F. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00824-4 · Cited by 145
Advances in the management of pancreatic cancer
Chiaro, M. D., Sugawara, T., Karam, S. D., & Messersmith, W. A. (2023) · BMJ · doi:10.1136/bmj-2022-073995 · Cited by 118
Ragupathi, A., Singh, M., Perez, A. M., & Zhang, D. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1133472 · Cited by 120
Varghese, A. M., Perry, M., Chou, J. F., Nandakumar, S., Muldoon, D. M., Erakky, A., Zucker, A., Fong, C. J., Mehine, M. M., Nguyen, B., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03362-3 · Cited by 122
Self-citationConsensus, debate, and prospective on pancreatic cancer treatments
Wang, J., Yang, J., Narang, A. K., He, J., Wolfgang, C. L., Li, K., & Zheng, L. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01613-x · Cited by 104
Clinical approaches to overcome PARP inhibitor resistance
Zou, Y., Zhang, H., Chen, P., Tang, J., Yang, S., Nicot, C., Guan, Z., Li, X., & Tang, H. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02355-1 · Cited by 118
Key Proteins of Replication Stress Response and Cell Cycle Control as Cancer Therapy Targets
Khamidullina, A. I., Abramenko, Y. E., Bruter, A. V., & Tatarskiy, V. V. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021263 · Cited by 73
Hilmi, M., Delaye, M., Muzzolini, M., Nicolle, R., Cros, J. F., Hammel, P. R., Cardot‐Ruffino, V., & Neuzillet, C. (2023) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(23)00207-8 · Cited by 75
Self-citationBooth, C. M., Eisenhauer, E. A., Gyawali, B., & Tannock, I. F. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.01423 · Cited by 75
Improving outcomes of patients with pancreatic cancer
Dreyer, S. B., Beer, P. A., Hingorani, S. R., & Biankin, A. V. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01019-9 · Cited by 71
BRCA1, BRCA2 , and Associated Cancer Risks and Management for Male Patients
Cheng, H. H., Shevach, J. W., Castro, E., Couch, F. J., Domchek, S. M., Eeles, R. A., Giri, V. N., Hall, M. J., King, M., Lin, D. W., et al. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2024.2185 · Cited by 63
Self-citationTreatment of metastatic pancreatic cancer: 25 years of innovation with little progress for patients
Gyawali, B., & Booth, C. M. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00516-8 · Cited by 62
PARP Inhibitors in Breast and Ovarian Cancer
Wang, S. S. Y., Jie, Y. E., Cheng, S. W., Ling, G. L., & Heong, V. Y. M. (2023) · Cancers · doi:10.3390/cancers15082357 · Cited by 60
Ikezawa, K., Urabe, M., Kai, Y., Takada, R., Akita, H., Nagata, S., & Ohkawa, K. (2023) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyad176 · Cited by 52
Current and Emerging Treatment Options for Pancreatic Cancer: A Comprehensive Review
Hayat, U., Croce, P., Saadeh, A., Desai, K., Appiah, J., Khan, S., Khan, Y. I., Kumar, K., & Hanif, A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041129 · Cited by 55
Zheng, S., Tian, Q., Yuan, Y., Sun, S., Li, T., Xia, R., He, R., Luo, Y., Lin, Q., Fu, Z., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02854-3 · Cited by 50
Next-generation therapies for pancreatic cancer
Buckley, C. W., & O'Reilly, E. M. (2024) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2024.2322648 · Cited by 49
Self-citationPancreatic cancer biomarkers: A pathway to advance in personalized treatment selection
Brozos-Vázquez, E., Toledano‐Fonseca, M., Costa‐Fraga, N., García‐Ortiz, M. V., Díaz‐Lagares, Á., Rodríguez‐Ariza, A., Aranda, E., & López‐López, R. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102719 · Cited by 50
Mannucci, A., & Goel, A. (2025) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.70035 · Cited by 54
Targeted Therapies in Pancreatic Cancer: A New Era of Precision Medicine
Li, B., Zhang, Q., Castaneda, C. N., & Cook, S. M. (2024) · Biomedicines · doi:10.3390/biomedicines12102175 · Cited by 38
He, R., Hu, C., Yuan, Y., Li, T., Tian, Q., Huang, T., Lin, Q., Zheng, S., Chen, C., Fu, Z., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07431-4 · Cited by 38
Polθ: emerging synthetic lethal partner in homologous recombination-deficient tumors
Russo, T. D. B., Mujacic, C., Giovanni, E. D., Vitale, M. C., Bannera, C. F., Randazzo, U., Contino, S., Bono, M., Gristina, V., Galvano, A., et al. (2024) · Cancer Gene Therapy · doi:10.1038/s41417-024-00815-2 · Cited by 39
Emerging Role of Targeted Therapy in Metastatic Pancreatic Adenocarcinoma
Huffman, B. M., Ellis, H., Jordan, A. C., Freed-Pastor, W. A., Perez, K. J., Rubinson, D. A., Sethi, N. S., Singh, H., Surana, R., Wolpin, B. M., et al. (2022) · Cancers · doi:10.3390/cancers14246223 · Cited by 31
Pancreatic Cancer: BRCA Targeted Therapy and Beyond
Keane, F., O'Connor, C. A., Park, W., Seufferlein, T. T. W., & O'Reilly, E. M. (2023) · Cancers · doi:10.3390/cancers15112955 · Cited by 26
Self-citationYavas, A., Özcan, K., Adsay, V. N., Balcı, S., Tarcan, Z. C., Hechtman, J. F., Luchini, C., Scarpa, A., Lawlor, R. T., Mafficini, A., et al. (2024) · Modern Pathology · doi:10.1016/j.modpat.2024.100585 · Cited by 24
Self-citationA pan‐tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitors
Chehade, C. H., Gebrael, G., Sayegh, N., Özay, Z. İ., Narang, A., Crispino, T., Golan, T., Litton, J. K., Swami, U., Moore, K. N., et al. (2025) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21870 · Cited by 28
Self-citationPark, W., O'Connor, C. A., Chou, J. F., Hilmi, M., Tarcan, Z. C., Schwartz, C., Larsen, M., Homsi, R., Sivaprakasam, K., Umeda, S., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04299-5 · Cited by 24
Self-citationNovel Therapies for Pancreatic Cancer
Chung, V., Mizrahi, J. D., & Pant, S. (2024) · JCO Oncology Practice · doi:10.1200/op.24.00279 · Cited by 20
The Landscape of PARP Inhibitors in Solid Cancers
Muzzana, M., Broggini, M., & Damia, G. L. M. (2025) · OncoTargets and Therapy · doi:10.2147/ott.s499226 · Cited by 19
Pancreatic organoids as cancer avatars for true personalized medicine
Gout, J., Ekizce, M., Roger, É., & Kleger, A. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115642 · Cited by 20
The war on pancreatic cancer: progress and promise
Iacobuzio–Donahue, C. A. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00728-1 · Cited by 18
Nanomedicine and epigenetics: New alliances to increase the odds in pancreatic cancer survival
Urbanova, M., Cihova, M., Buociková, V., Slopovský, J., Dubovan, P., Pinďák, D., Tomáš, M., García‐Bermejo, L., Rodríguez-Garrote, M., Earl, J., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115179 · Cited by 19
The trend toward more target therapy in pancreatic ductal adenocarcinoma
Deiana, C., Agostini, M., Brandi, G., & Giovannetti, E. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2357802 · Cited by 17
New Therapeutic Options for BRCA Mutant Patients
Ghanem, A., & Domchek, S. M. (2024) · Annual Review of Medicine · doi:10.1146/annurev-med-082523-083843 · Cited by 17
Γκουντάκος, Α., Martelli, F. M., Silvestris, N., Bevere, M., Bellis, M. D., Alaimo, L., Sapuppo, E., Masetto, F., Mombello, A., Simbolo, M., et al. (2023) · Cancers · doi:10.3390/cancers15051454 · Cited by 18
Unveiling the Promise: Navigating Clinical Trials 1978–2024 for PDAC
Dominguez, A. A., Perz, M., Xu, Y., Cedillo, L. G., Huang, O. L., McIntyre, C. A., Vudatha, V., Trevino, J. G., Liu, J., & Wang, P. (2024) · Cancers · doi:10.3390/cancers16213564 · Cited by 17
The incidence of pancreatic cancer in women with a BRCA1 or BRCA2 mutation
Katona, B. W., Lubiński, J., Pal, T., Huzarski, T., Foulkes, W. D., Møller, P., Eisen, A. F., Armel, S. R., Neuhausen, S. L., Raj, R., et al. (2024) · Cancer · doi:10.1002/cncr.35666 · Cited by 16
Personalized Systemic Therapies in Hereditary Cancer Syndromes
Mastrodomenico, L., Piombino, C., Riccò, B., Barbieri, E., Venturelli, M., Piacentini, F., Dominici, M., Cortesi, L., & Toss, A. (2023) · Genes · doi:10.3390/genes14030684 · Cited by 17
Pancreatic cancer: failures and hopes—a review of new promising treatment approaches
Cereda, V., & D'Andrea, M. R. (2025) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2025.1002299 · Cited by 16
State of the Art: ctDNA in Upper Gastrointestinal Malignancies
Labiano, I., Huerta, A. E., Arrazubi, V., Hernández-García, I., Mata, E., Gómez, D., Arasanz, H., Vera, R., & Alsina, M. (2023) · Cancers · doi:10.3390/cancers15051379 · Cited by 15
Reißig, T. M., Tzianopoulos, I., Liffers, S.-T., Rosery, V., Guyot, M., Ting, S., Wiesweg, M., Kasper, S., Meister, P., Herold, T., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.101539 · Cited by 15
The role of molecular testing in pancreatic cancer
Zhen, D. B., Safyan, R. A., Konick, E. Q., Nguyen, R., Pritchard, C. C., & Chiorean, E. G. (2023) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848231171456 · Cited by 16
Emerging Prognostic and Predictive Factors in Pancreatic Cancer
Karamitopoulou, E. (2023) · Modern Pathology · doi:10.1016/j.modpat.2023.100328 · Cited by 16
Beyond BRCA: Diagnosis and management of homologous recombination repair deficient pancreatic cancer
LaRose, M., Manji, G. A., & Bates, S. E. (2023) · Seminars in Oncology · doi:10.1053/j.seminoncol.2023.11.001 · Cited by 16
Strategies for the prevention or reversal of PARP inhibitor resistance
Mitri, Z. I., Goodyear, S. M., & Mills, G. B. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2393251 · Cited by 15
Redegalli, M., Grassini, G., Magliacane, G., Pecciarini, L., Lena, M. S., Smart, C. E., Johnston, R. L., Waddell, N., Maestro, R., Macchini, M., et al. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.10.014 · Cited by 15
Self-citationSMAD4 Limits PARP1 dependent DNA Repair to Render Pancreatic Cancer Cells Sensitive to Radiotherapy
Wang, Y., Yu, T., Zhao, Z., Li, X., Song, Y., He, Y., Zhou, Y., Li, P., An, L., & Wang, F. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-07210-7 · Cited by 14
PARP inhibitor therapy in patients with IDH1 mutated cholangiocarcinoma
Mohan, A., Quingalahua, E. C., Gunchick, V., Paul, S., Kumar‐Sinha, C., Crysler, O., Zalupski, M. M., & Sahai, V. (2024) · The Oncologist · doi:10.1093/oncolo/oyae163 · Cited by 12
M'Baloula, J., Tougeron, D., Boilève, A., Jeanbert, E., Guimbaud, R., Abdelghani, M. B., Durand, A., Turpin, A., Quesada, S., Blanc, J. F., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.115051 · Cited by 11
Chen, C., Lu, F., Huang, H., & Pan, Y. (2024) · iScience · doi:10.1016/j.isci.2024.111478 · Cited by 13
Lee, C. L., Holter, S., Borgida, A., Dodd, A., Ramotar, S., Grant, R. C., Wasson, K., Elimova, E., Jang, R. W., Moore, M. J., et al. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i45.6421 · Cited by 11
Fiorentini, G., Sarti, D., Mambrini, A., Ferri, I. H., Bonucci, M., Sciacca, P. G., Ballerini, M., Bonanno, S., Milandri, C., Nani, R., et al. (2023) · World Journal of Clinical Oncology · doi:10.5306/wjco.v14.i6.215 · Cited by 10
Miao, R., Blue, K., Sommerer, K. R., Shah, A., Bottiglieri, S., Cueto, A. D., Berry, D. K., Ho, T. T., Hicks, J. K., & Kim, D. W. (2024) · Cancers · doi:10.3390/cancers16203447 · Cited by 12
Gales, L. N., Păun, M.-A., Butnariu, I., Simion, L., Manolescu, L. S. C., Trifanescu, O. G., & Anghel, R. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073123 · Cited by 12
Emerging Therapeutic Approaches to Pancreatic Adenocarcinoma: Advances and Future Directions
Peng, C., & Oberstein, P. E. (2025) · Current Treatment Options in Oncology · doi:10.1007/s11864-025-01352-2 · Cited by 14
Xiang, J., Li, J., Guo, Z., Wu, J., Ma, D., Xu, H., Shang, T., Pu, P., Cong, L., Zhou, R., et al. (2026) · Biomarker Research · doi:10.1186/s40364-026-00908-0 · Cited by 11
Rosso, C., Marciano, N. D., Nathan, D., Chen, W., McLaren, C. E., Osann, K., Flodman, P. L., Cho, M. T., Lee, F.-C., Dayyani, F., et al. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.7333 · Cited by 9
Efficacy assessment in phase I clinical trials: endpoints and challenges
Gouda, M., Ballesteros, P. A., Garrido-Laguna, I., & Rodon, J. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.02.010 · Cited by 8
Urbach, L., Wieland, L., Penz, F., Samuel, R. D., Küffer, S., Klein, L., Lenz, C., Sax, U., Ghadimi, M. B., Schulz‐Heddergott, R., et al. (2025) · Science Advances · doi:10.1126/sciadv.adu2339 · Cited by 10
Xu, Q., Wen, Y., Huang, T., Li, H., Liu, X., Shi, S.-N., Gong, W., Mills, G. B., Ma, D., Gao, Q., et al. (2025) · Biomarker Research · doi:10.1186/s40364-025-00814-x · Cited by 10
Actionable mutations in pancreatic cancer: where targeted therapies are making a difference
Fivaz, M., Bornand, A., Corrò, C., Koessler, T., & Genoud, V. (2025) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2025-001925 · Cited by 9
Kindler, H. L., Yoo, H. K., Hettle, R., Cui, K. Y., Joo, S., Locker, G. Y., & Golan, T. (2023) · Cancer · doi:10.1002/cncr.34610 · Cited by 9
Self-citationDai, M., Wang, X., Xin, W., Kong, S., Xu, W., Ding, H., & Fang, L. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2357822 · Cited by 9
Xu, T., Schulga, A. A., Коновалова, Е. В., Rinne, S. S., Zhang, H., Vorontsova, O. V., Orlova, A., Deyev, S. M., Максимилианович, Т. В., & Vorobyeva, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032838 · Cited by 9
Germline Pathogenic Variants in Patients With Pancreatic and Periampullary Cancers
Ando, Y., Dbouk, M. H., Yoshida, T., Diwan, E. A., Saba, H., Dbouk, A., Yoshida, K., Roberts, N. J., Klein, A. P., Burkhart, R. A., et al. (2024) · JCO Precision Oncology · doi:10.1200/po.24.00101 · Cited by 10
Sha, X., Li, J., Fang, Y., Feng, J., Ye, F., Wang, J., Si, Y., Li, F., Cheng, S., & Ding, W. (2025) · BMC Cancer · doi:10.1186/s12885-025-14568-0 · Cited by 8
Lyubetskaya, A., Rabe, B. A., Kavran, A. J., Bai, Y., Fisher, A., Font‐Tello, A., Lewin, A. C., Pliner, H. A., Fan, Y., Giampapa, L., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2025.116827 · Cited by 10
Targeting BRCA and PALB2 in Pancreatic Cancer
Anbil, S. R., & Reiss, K. A. (2024) · Current Treatment Options in Oncology · doi:10.1007/s11864-023-01174-0 · Cited by 9
Nicolle, R., Canivet, C., Palazzo, L., Napoléon, B., Ayadi, M., Pignolet, C., Cros, J. F., Gourgou, S., Sèlves, J., Torrisani, J., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105373 · Cited by 8
Voutsadakis, I. A., & Digklia, A. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45030135 · Cited by 8
Clinical Actionability of Genes in Gastrointestinal Tumors
Gonzalez, N. S., Patelli, G., & Crisafulli, G. (2025) · Genes · doi:10.3390/genes16101130 · Cited by 7
Chen, Z., Wang, K., Zhao, L., & Gong, L. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1190100 · Cited by 7
Knipper, K., Hussein, Y., Simon, A. G., Fretter, C., Damanakis, A. I., Zhao, Y., Bruns, C. J., Schmidt, T., Popp, F., Quaas, A., et al. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05681-x · Cited by 7
Molecular imaging of PARP in cancer: state-of-the-art
Filippi, L., Urso, L., Frantellizzi, V., Marzo, K., Marzola, M. C., Schillaci, O., & Evangelista, L. (2023) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2023.2287503 · Cited by 7
Advances in Drug Therapy for Metastatic Pancreatic Ductal Adenocarcinoma
Gao, J., Wang, J., Guan, C., Shi, W., Dong, Q., Sheng, J., Zou, X., Xu, Z., Ge, Y., Huang, Z., et al. (2024) · Journal of Cancer · doi:10.7150/jca.89788 · Cited by 7
Bahng, I. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1713123 · Cited by 6
Valdez, B. C., Tsimberidou, A. M., Yuan, B., Nieto, Y. L., Baysal, M. A., Chakraborty, A., Andersen, C. R., & Andersson, B. S. (2024) · Oncotarget · doi:10.18632/oncotarget.28588 · Cited by 6
Development of a Novel Protocol for Germline Testing in Pancreatic Cancer
McDonald, H. G., Kennedy, A., Solomon, A. L., Williams, C. M., Reagan, A. M., Cassim, E., Harper, M. M., Burke, E. E., Armstrong, T., Gosky, M., et al. (2024) · Annals of Surgical Oncology · doi:10.1245/s10434-024-16011-3 · Cited by 6
Morimoto, Y., Takada, K., Nakano, A., Takeuchi, O., Watanabe, K., Hirohara, M., & Masuda, Y. (2024) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-024-04716-x · Cited by 6
Molecular Targeted Therapy in Oncology Focusing on DNA Repair Mechanisms
Garzón-Hernández, C., Ramírez-Merino, N., & Soberón, M. C. M. (2022) · Archives of Medical Research · doi:10.1016/j.arcmed.2022.11.007 · Cited by 7
Are Aspects of Integrative Concepts Helpful to Improve Pancreatic Cancer Therapy?
Oei, S. L., & Schad, F. (2023) · Cancers · doi:10.3390/cancers15041116 · Cited by 6
DeJongh, J., Cadogan, E. B., Davies, M. A., Ramos‐Montoya, A., Smith, A., van Steeg, T. J., & Richards, R. (2025) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-025-09962-x · Cited by 4
Luo, X., Gao, S., Sun, K., Dong, Z., & Yang, S. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1702121 · Cited by 6
Genomic evolution of pancreatic cancer at single-cell resolution
Zhang, H., Sashittal, P., Karnoub, E.-R. R., Jakatdar, A., Umeda, S., Hong, J., Noronha, A. M., Cardenas, A., Erakky, A., McIntyre, C. A., et al. (2026) · Nature Genetics · doi:10.1038/s41588-025-02468-9 · Cited by 5
Self-citationThe PARG frontier: mechanisms of PAR turnover and opportunities in precision oncology
Catara, G., Gerace, G., Lauro, R., & Palazzo, L. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.117770 · Cited by 5
Novel therapeutic strategies in pancreatic cancer: moving beyond cytotoxic chemotherapy
Geerinckx, B., Teuwen, L.-A. M. N., Foo, T., Vandamme, T., Smith, A., Peeters, M., & Price, T. J. (2023) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2270161 · Cited by 5
Updates in Molecular Profiling of Pancreatic Ductal Adenocarcinoma
Lee, J. J., & Yeh, J. J. (2024) · Surgical Clinics of North America · doi:10.1016/j.suc.2024.04.001 · Cited by 5
Li, Y., Xiong, X., Liu, X., Xu, M., Yang, B., Li, X., Yu, L., Lin, B., & Xu, B. (2024) · Annals of Medicine · doi:10.1080/07853890.2024.2399759 · Cited by 5
Reni, M., Peretti, U., Macchini, M., Orsi, G., Militello, A.-M., Briccolani, A., Falconi, M., & Cascinu, S. (2023) · Digestive and Liver Disease · doi:10.1016/j.dld.2023.07.033 · Cited by 5
Self-citationSeligson, N. D., Kolesar, J., Alam, B., Baker, L., Lamba, J. K., Fridley, B. L., Salahudeen, A. A., Hertz, D. L., & Hicks, J. K. (2023) · Pharmacogenomics · doi:10.2217/pgs-2023-0125 · Cited by 5
Emerging pathways yielding opportunities for future treatments in pancreatic ductal adenocarcinoma
Shah, A., Johnson, E., Ponnusamy, M. P., & Batra, S. K. (2025) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2025.2507035 · Cited by 4
The Landmark Series: Neoadjuvant Therapy for Resectable Pancreatic Cancer
Cardell, C. F., Dekker, E. N., Katz, M. H. G., & Tzeng, C.-W. D. (2025) · Annals of Surgical Oncology · doi:10.1245/s10434-025-17736-5 · Cited by 4
Lin, H., Zhou, J., Li, Y., Luo, L., Zeng, Y., Liang, X., Yu, J., Ye, C., Yang, P., Lin, Y., et al. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117199 · Cited by 4
Beutel, A. K., Halbrook, C. J., Ekizce, M., Lindenmayer, J., Roger, É., Calderon, S. E., Seufferlein, T. T. W., Kleger, A., Gout, J., & Perkhofer, L. (2025) · United European Gastroenterology Journal · doi:10.1002/ueg2.12773 · Cited by 4
Kawanaka, Y., Inagaki, C., Okura, M., Mitani, S., Takahama, T., Yonesaka, K., Chiba, Y., Nakagawa, K., Kawakami, H., & Hayashi, H. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1570731 · Cited by 4
Universal Genetic Testing for Pancreatic Cancer: Closing the Gap on a Missed Opportunity
Sanoba, S., & Wadlow, R. C. (2025) · JCO Oncology Practice · doi:10.1200/op-25-00154 · Cited by 4
Metadata
- Authors
- Kindler, H. L., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., Park, J. O., Hochhauser, D., Arnold, D., Oh, D.-Y., Reinacher-Schick, A., Tortora, G., Algül, H., O'Reilly, E. M., Bordia, S., McGuinness, D., Cui, K., Locker, G. Y., & Golan, T.
- Affiliations
- University of Chicago (US)
- Université Paris-Saclay (FR)
- IRCCS Ospedale San Raffaele (IT)
- University Hospitals Gasthuisberg and KU Leuven, Leuven, Belgium
- Vall d'Hebron Hospital Universitari (ES)
- Fox Chase Cancer Center (US)
- Samsung Medical Center (KR)
- University College London (GB)
- Asklepios Klinik Altona (DE)
- Seoul National University (KR)
- St Josef-Hospital, Ruhr University Bochum, Bochum, Germany
- Università Cattolica del Sacro Cuore (IT)
- TUM Klinikum (DE)
- Memorial Sloan Kettering Cancer Center (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- AstraZeneca (United Kingdom) (GB)
- AstraZeneca (United States) (US)
- Tel Aviv University (IL)
- ORCID
- Venue
- Journal of Clinical Oncology
- Published
- 2022-12-01
- Volume
- 40
- Issue
- 34
- Pages
- 3929-3939
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- PMC
- PMC10476841
- OpenAlex
- W4285386328
- Cited by
- 244
- References
- 39
- Citations by year
- 2026: 60 · 2025: 68 · 2024: 59 · 2023: 48 · 2022: 9
- FWCI
- 19.25
- Type
- journal article
- Language
- en
- Update notices
- correction (2024-04-30)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- American Society of Clinical Oncology
- Alnylam Pharmaceuticals
- Celgene
- FibroGen
- Array BioPharma
- Boston Scientific Corporation
- Merck KGaA
- Taiho Pharmaceutical
- Exelixis
- Novocure
- Les Laboratories Pierre Fabre
- Halozyme
- Mylan
- Constellation Pharmaceuticals
- BeiGene
- Incyte
- MacroGenics
- Eisai
- Astellas Pharma
- European Society for Medical Oncology
- Servier
- Swedish Orphan Biovitrum
- Ipsen
- Sirtex Medical
- Aptitude Health
- National Institutes of Health (CA008748)
- Genentech
- EMD Serono
- Chugai Pharmaceutical
- National Cancer Institute (CA008748, P30- 17 CA008748, P30CA008748)
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Keywords
- olaparib, maintenance therapy, germline BRCA mutation, metastatic pancreatic adenocarcinoma, PARP inhibitors, overall survival, progression-free survival, platinum-based chemotherapy, secondary malignancies, PARP inhibitor resistance, treatment discontinuation, safety and tolerability
- MeSH terms
- Adenocarcinoma, Female, Germ Cells, Humans, Neoplasm Recurrence, Local, Ovarian Neoplasms, Pancreatic Neoplasms, Phthalazines, Piperazines, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
